These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8368736)

  • 1. Clinical trials with VMO for melanoma.
    Wallack MK; Sivanandham M
    Ann N Y Acad Sci; 1993 Aug; 690():178-89. PubMed ID: 8368736
    [No Abstract]   [Full Text] [Related]  

  • 2. Augmentation of T-cell response with a melanoma cell vaccine expressing specific HLA-A antigens.
    Hoon DS; Morisaki T; Uchiyama A; Hayashi Y; Foshag LJ; Nizze AJ; Morton DL
    Ann N Y Acad Sci; 1993 Aug; 690():343-5. PubMed ID: 8368751
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens.
    Bystryn JC
    Ann N Y Acad Sci; 1993 Aug; 690():190-203. PubMed ID: 8368738
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo.
    Oertli D; Marti WR; Zajac P; Noppen C; Kocher T; Padovan E; Adamina M; Schumacher R; Harder F; Heberer M; Spagnoli GC
    Hum Gene Ther; 2002 Mar; 13(4):569-75. PubMed ID: 11874634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for malignant melanoma with a tumor cell vaccine.
    Slingluff CL; Seigler HF
    Ann Plast Surg; 1992 Jan; 28(1):104-7. PubMed ID: 1642395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-idiotypes in melanoma.
    Ferrone S
    Hybridoma; 1993 Oct; 12(5):509-14. PubMed ID: 8300123
    [No Abstract]   [Full Text] [Related]  

  • 7. Active specific immunotherapy with vaccinia melanoma oncolysate.
    Wallack MK; Scoggin SD; Sivanandham M
    Mt Sinai J Med; 1992 May; 59(3):227-33. PubMed ID: 1318507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy with MAGE antigens.
    Coulie PG
    Suppl Tumori; 2002; 1(4):S63-5. PubMed ID: 12415826
    [No Abstract]   [Full Text] [Related]  

  • 9. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action.
    Mitchell MS; Harel W; Kan-Mitchell J; LeMay LG; Goedegebuure P; Huang XQ; Hofman F; Groshen S
    Ann N Y Acad Sci; 1993 Aug; 690():153-66. PubMed ID: 8368734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of melanoma: peptide mimics of a human high molecular weight-melanoma associated antigen.
    Wang X; Luo W; Ferrone S
    Medicina (B Aires); 2000; 60 Suppl 2():48-50. PubMed ID: 11188931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunological analysis of melanoma-specific antigen].
    Wakabayashi S; Okamoto S
    Nihon Hifuka Gakkai Zasshi; 1985 Oct; 95(11):1145-51. PubMed ID: 3879298
    [No Abstract]   [Full Text] [Related]  

  • 12. Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate.
    Scoggin SD; Sivanandham M; Sperry RG; Wallack MK
    Ann Plast Surg; 1992 Jan; 28(1):108-9. PubMed ID: 1642396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genes coding for antigens recognized on human tumors by autologous cytolytic T lymphocytes.
    Coulie P; Weynants P; Muller C; Lehmann F; Herman J; Baurain JF; Boon T
    Ann N Y Acad Sci; 1993 Aug; 690():113-9. PubMed ID: 8368730
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy.
    Boon T
    Int J Cancer; 1993 May; 54(2):177-80. PubMed ID: 8486420
    [No Abstract]   [Full Text] [Related]  

  • 15. Melanoma antigens: immunological and biological characterization and clinical significance.
    Herlyn M; Koprowski H
    Annu Rev Immunol; 1988; 6():283-308. PubMed ID: 3289568
    [No Abstract]   [Full Text] [Related]  

  • 16. Cancer. Cancer immunotherapy is more than a numbers game.
    Offringa R
    Science; 2006 Oct; 314(5796):68-9. PubMed ID: 17023641
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cytotoxic T-cell immune response against melanoma antigens].
    Ayyoub M
    Ann Dermatol Venereol; 1998 Nov; 125 Suppl 2():S34-6. PubMed ID: 9922891
    [No Abstract]   [Full Text] [Related]  

  • 18. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of tumor-regression antigens in melanoma.
    Kawakami Y; Robbins PF; Wang RF; Rosenberg SA
    Important Adv Oncol; 1996; ():3-21. PubMed ID: 8791125
    [No Abstract]   [Full Text] [Related]  

  • 20. Human tumor immunotherapy. New opportunities as well as new challenges.
    Cerottini JC; Valmori D; Rimoldi D; Romero P
    Adv Exp Med Biol; 1998; 451():247-50. PubMed ID: 10026881
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.